NanoViricides, Inc. (NNVC)
NYSEAMERICAN: NNVC · Real-Time Price · USD
1.460
0.00 (0.00%)
At close: May 6, 2026, 4:00 PM EDT
1.480
+0.020 (1.37%)
Pre-market: May 7, 2026, 8:04 AM EDT
NanoViricides Employees
NanoViricides had 7 employees as of June 30, 2025. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,188,349
Market Cap
31.53M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 7 | 0 | - |
| Jun 30, 2024 | 7 | 0 | - |
| Jun 30, 2023 | 7 | -10 | -58.82% |
| Jun 30, 2022 | 17 | 0 | - |
| Jun 30, 2021 | 17 | 0 | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| IGC Pharma | 70 |
| NextCure | 40 |
| Werewolf Therapeutics | 39 |
| Senti Biosciences Holdings | 39 |
| Lisata Therapeutics | 21 |
| Tevogen Bio Holdings | 18 |
| Quantum BioPharma | 17 |
NNVC News
- 16 hours ago - NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference - Newsfile Corp
- 3 days ago - NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA - Accesswire
- 16 days ago - Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides - Accesswire
- 4 weeks ago - Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides - Accesswire
- 5 weeks ago - Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides - Accesswire
- 2 months ago - NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete - Accesswire
- 2 months ago - MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - Accesswire
- 3 months ago - Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - Accesswire